At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09926 AKESO
Trading 05-16 15:15:56
49.550
+0.350
+0.71%
High50.650Low49.350Vol2.99M
Open50.200D1 Closing49.200Amplitude2.64%
Mkt Cap42.90BTradable Cap42.90BTotal Shares865.86M
T/O149.42MT/O Rate0.35%Tradable Shares865.86M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price
Simply Wall St.  ·  04-25
Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price
BRIEF-Akeso Says NMPA Accepted Supplemental New Drug Application For Cadonilimab
Reuters  ·  04-24
BRIEF-Akeso Says NMPA Accepted Supplemental New Drug Application For Cadonilimab
Akeso Marks Profit Milestone With Swift Rights Issue
seekingalpha  ·  03-28
Akeso Marks Profit Milestone With Swift Rights Issue
We Think Akeso's (HKG:9926) Robust Earnings Are Conservative
Simply Wall St.  ·  03-26
We Think Akeso's (HKG:9926) Robust Earnings Are Conservative
BUZZ-Biological products developer Akeso falls on discounted share sale
Reuters  ·  03-21
BUZZ-Biological products developer Akeso falls on discounted share sale
BRIEF-Akeso Announces Placing Of New Shares Under General Mandate
Reuters  ·  03-21
BRIEF-Akeso Announces Placing Of New Shares Under General Mandate
Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Simply Wall St.  ·  03-21
Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Akeso Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St.  ·  03-20
Akeso Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
BRIEF-Akeso Says FY Profit RMB1,942.4 Million
Reuters  ·  03-18
BRIEF-Akeso Says FY Profit RMB1,942.4 Million
Akeso, Inc. (HKG:9926) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Simply Wall St.  ·  03-08
Akeso, Inc. (HKG:9926) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
BRIEF-Akeso Sees Profit Of Not Less Than RMB1.85 Billion During Year
Reuters  ·  03-05
BRIEF-Akeso Sees Profit Of Not Less Than RMB1.85 Billion During Year
BRIEF-Akeso Says Unit To Purchase 35% Stake In Ad Pharmaceuticals For Rmb267.4 Mln
Reuters  ·  02-09
BRIEF-Akeso Says Unit To Purchase 35% Stake In Ad Pharmaceuticals For Rmb267.4 Mln
Institutions along with individual investors who hold considerable shares inAkeso, Inc. (HKG:9926) come under pressure; lose 6.0% of holdings value
Simply Wall St.  ·  02-02
Institutions along with individual investors who hold considerable shares inAkeso, Inc. (HKG:9926) come under pressure; lose 6.0% of holdings value
BRIEF-Akeso Presented Promising Results Of Cadonilimab And Lenvatinib In Combination With Tace In Uhcc At 2024 Asco Gi
Reuters  ·  01-23
BRIEF-Akeso Presented Promising Results Of Cadonilimab And Lenvatinib In Combination With Tace In Uhcc At 2024 Asco Gi
BRIEF-Akeso Says NMPA Accepted Supplemental New Drug Application For Cadonilimab In Combination With Chemotherapy As First-Line Treatment For Gastric Cancer
Reuters  ·  01-05
BRIEF-Akeso Says NMPA Accepted Supplemental New Drug Application For Cadonilimab In Combination With Chemotherapy As First-Line Treatment For Gastric Cancer
Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price
Simply Wall St.  ·  2023-12-28
Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price
Is Akeso, Inc.'s (HKG:9926) Latest Stock Performance A Reflection Of Its Financial Health?
Simply Wall St.  ·  2023-12-07
Is Akeso, Inc.'s (HKG:9926) Latest Stock Performance A Reflection Of Its Financial Health?
ADVISORY-Alert wrongly tagged to Lenovo Group Ltd withdrawn
Reuters  ·  2023-12-05
ADVISORY-Alert wrongly tagged to Lenovo Group Ltd withdrawn
BRIEF-Akeso's Cadonilimab Met Primary Endpoint Of Progression-Free Survival In Phase III Trial For First-Line Treatment Of Recurrent/Metastatic Cervical Cancer In All-Comer Patients
Reuters  ·  2023-11-27
BRIEF-Akeso's Cadonilimab Met Primary Endpoint Of Progression-Free Survival In Phase III Trial For First-Line Treatment Of Recurrent/Metastatic Cervical Cancer In All-Comer Patients
BUZZ-China's Akeso rises on progress of cervical cancer drug
Reuters  ·  2023-11-23
BUZZ-China's Akeso rises on progress of cervical cancer drug

Introduction

Company Name.
AKESO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.
Issue price:
--